Serum triiodothyronine (T 3 ) has been measured by radioimmunoassay and corroborated by analysis of the identical samples with a previously described gas-liquid chromatographic technique. Special features of the radioimmunoassay procedure which permit determinations in unextracted serum include the use of a T 3 -free serum preparation for the construction of the standard curve and of tetrachlorothyronine to inhibit binding of T 3 to thyroxine-binding globulin.
INTRODUCTION
L-3,5,3'-Triiodothyronine (T3)' discovered in 1952 (1) , has been, shown to have a higher metabolic potency, a more rapid turnover, and a larger volume of distribution in the body than thyroxine (T4) (2) . Therefore, despite its low concentration in serum relative to T4, T3 apparently contributes a substantial proportion of the metabolic activity of the thyroid hormones (2) . It was reported shortly after the discovery of T3 that T4 might exert its effect at the tissue level predominantly via conversion to T3 (3) . The suggestion that there is a peripheral conversion of T4 to T3 has recently been restated (4) (5) (6) . Hollander called attention to a hyperthyroid state in which an elevated Ta concentration appears to be the major pathogenic factor (7, 8) , a syndrome he named T3 toxicosis. Subsequently another group has reported on a similar group of patients (9) .
These findings emphasize the physiologic and clinical significance of the hormone and the desirability for an accurate method for its measurement in serum suitable .for clinical use. At present, there is little consensus with regard to the actual concentrations of Ts in serum. Recent estimates of serum T3 levels in normal subjects by a number of workers using a variety of techniques (7, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) have varied over a ninefold range. The excellent agreement found, between the measurements by the radioimmunoassay technique reported here and those 'Abbreviations used in this paper: BSA, bovine serum albumin; LATS, long-acting thyroid stimulator; PBI, protein-bound iodine; T,, serum triiodothyronine; T4, thyroxine; TBG, thyroxine-binding globulin; TRH, thyrotropinreleasing hormone; TSH, thyroid-stimulating hormone.
The Journal of Clinical Investigation Volume 50 1971 2679 of gas chromatography (10) serve to corroborate the validity of these two entirely independent methods. The inherent simplicity and rapidity of the radioimmunoassay procedure renders it most suitable for routine clinical use for the measurement of serum Ts.
METHODS
The radioimmunoassay method for the measurement of T8 has two unique features which permit measurements in unextracted serum: (a) the use of tetrachlorothyronine, a known inhibitor of T4 binding to thyroxine-binding globulin (TBG) (23) to inhibit the binding of Ta-'"I to TBG and displace endogenous Ta from TBG; (b) the standard curves have been constructed utilizing a T3-free serum as diluent.
Detailed procedure
Production of antiserum to Ts. T3 immunogen was prepared by two methods from a purified preparation. Ts was obtained as the free acid (Sigma Chemical Co, St. Louis, Mo.) and purified by five consecutive paper chromatographic separations in a t-amyl alcohol: hexane: ammonia system (18) to a constant specific activity as previously described (10) .
The first procedure, a modification of the method of Brown, Ekins, Ellis, and Reith (24) , involved three steps and resulted in the formation of a Ts-poly-L-lysine conj ugate. (a) Preparation of methyl Ta: chromographically purified Ta was methylated as previously described (10) . (b) Preparation of succinylated poly-L-lysine: pOly-Llysine (Sigma Chemical Co.) was reacted with succinic anhydride (Eastman Organic Chemical Corp., Rochester, N. Y.) according to the method of Haber, Page, and Jacoby (25) . (c) Coupling of the methyl-ester of T3 to succinylated poly-L-lysine: using the method of Brown et al. (24) , the succinylated product was condensed with the methylester of Ta by coupling with carbodiimide (Sigma Chemical Co.).
The second method, a modification of the procedures of Oliver, Parker, Brasfield, and Parker (26) and Chopra, Nelson, Solomon, and Beall (27) , consisted of the direct coupling of Ts to bovine serum albumin to produce a T3-bovine serum albumin conjugate. 50 mg of chromatographically purified Ta was dissolved in 2.5 ml of 0.15 N NaOH and added with stirring into a solution of 100 mg bovine serum albumin (BSA; Sigma Chemical Co.) dissolved in 5 ml of distilled, deionized water. 300 mg of carbodiimide was then added with continued stirring and the pH of the reaction adjusted to 9.0 with hydrochloric acid. The mixture was incubated at 4°C overnight and dialyzed for 5 days against 6 liters of distilled, deionized water which was changed daily.
The resulting immunogens, emulsified in complete Freund's adjuvant (Difco Labs, Detroit, Mich.) (0.75 mg/0.2 ml) were injected into the toe-pads of the rabbits. This amount of immunogen was administered at the same site at 4, 6, 8, and 9 wk after the initial injection and blood for antiserum was drawn 1 wk after the last dose and every 2 wk thereafter. 50 adult 2700 g female rabbits of the New Zealand white strain (Zartman Farms, Douglasville, Pa.) were immunized with the Ts-poly-L-lysine conjugate, and five with the Ta-BSA conjugate.
Detection of antibody. T8-'I (Abbott Laboratories) was chromatographically purified (see above) before use. Barbital buffer, 0.08 M, containing 1 g/liter of bovine serum albumin to prevent adsorption to glassware (barbital diluent) was used for dilution of the antisera, radioactive Ts (T8-'I), and subsequently for test samples (see below).
Rabbit serum in dilutions of 1:10, 1: 50, 1:100, and 1: 500 was screened for the presence of antibody to Ts in the following manner. 30 pg of Ta-'I (SA 70-90 ACif/lg; Abbott Laboratories, North Chicago, Ill.) was added to 0.1 ml of the diluted test antiserum. The mixture was incubated at 4°C for 24 hr. After incubation, 0.2 ml of a slurry of activated charcoal and methyl cellulose in barbital diluent prepared as previously described (24, 28) was added, the mixture reincubated for 5 min, centrifuged at approximately 675 g for 15 min, the supernatant decanted, and the bound-to-free ratio determined as described below in the section on preparation of standard curves. A B/F ratio in excess of 2 at the lower dilutions (1: 10, 1: 50), which indicated the presence of potentially usable antibody, was found in 10 of 50 animals immunized with the poly-Llysine conjugate. Subsequently, antisera to the T8-BSA conjugate were analyzed and potentially usable antibody was found in all five animals. Four antisera which had the best antibody titers to Ts were employed for the Ts radioimmunoassays described in this report; two were harvested at 12 wk from an animal immunized with the T3-POIY-Llysine conjugate; two others were collected at 9 wk from a rabbit which had received the To-BSA conjugate.
Inhibition A similar curve was constructed in barbital buffer, i. e. in the absence of Ts-free serum, for Ts, T4, and tetrachlorothyronine. Ta and T4 were obtained as the free acids (Sigma Chemical Co.), T3 was purified as described above. T4 was also further purified. A tracer quantity of T4-AI (Abbott Laboratories) was added at the outset (10,000 dpm/ng of T4). The resultant mixture was purified by column chromatography on Sephadex LH 20 (30) followed by five successive paper chromatographic separations in a t-amyl alcohol system (18) until a constant specific activity had been achieved. Gas chromatographic analysis (10) of the purified T4 preparation indicated that its T3 content was less than 0.01%.
A series of curves was also determined for L-monoiodothyronine, L-3,5-diiodothyronine, L-monoiodotyrosine, L-diiodotyrosine, triiodothyroacetic acid, and poly-L-lysine. All of these were obtained from the Sigma Chemical Co. and had been purified chromatographically by the manufacturer.
Analysis of unknozen sera. Mixtures of unknown samples were prepared in an identical manner and at the same time as were the standard solutions, except that 0.1 ml of serum, which had been diluted 1: 4 in barbital buffer, was substituted for the test standard at the outset of the procedure so that 0.025 ml of the original serum was actually assayed. The Ta concentration in the serum sample was determined by comparing the B/F ratio obtained with it with the standard curve. All measurements were the means of quadruplicate determinations.
Clinical material. Normal subjects were clinically euthyroid, had no palpable enlargement of the thyroid gland, and had normal levels of protein-bound iodine (PBI; Bioscience Labs., Van Nuys, Calif.) or T4 by competitive binding analysis (Boston Medical Labs., Boston, Mass.) and had a normal free T4 determination (Bioscience Labs.). Untreated hyperthyroid patients were clinically toxic, had an elevated PBI or T4, a high free T4, and an abnormally increased thyroidal uptake of radioiodine. 60 subjects had toxic diffuse goiter, i.e., a diffusely enlarged thyroid gland with no nodules on palpation and a diffuse uptake of radioiodine on scan. Four subjects had toxic multinodular goiter. In these cases the thyroidal uptake of radioiodine was localized to one or more discrete nodules.
Patients considered to have T8 toxicosis on the basis of their clinical presentation and an elevation in the serum Ts level (7, 8) will be more fully described in the results section.
Patients with treated hyperthyroidism had received radioiodine, undergone surgery, or were taking antithyroid drugs. They were adjudged to be clinically euthyroid and had normal determinations of the PBI and T4 by the MurphyPattee method, free T4, and a normal uptake of radioiodine.
Patients with hypothyroidism were clinically hypothyroid and had abnormally low PBI or To, free T4, and radio-NANOGRAMS PER TUBE FIGURE 1 Cross-reaction of T8 antibody with other thyroid analogues. The Ts standard curve in buffer (open triangles) shows a sensitivity to Ta in the picogram range. Note the breaks on both the vertical axis which is plotted on an arithmetic scale and in the horizontal axis which is on a logarithmic scale. The extent of cross-reaction between the Ts antibody and a chromatographically purified To preparation (open circles) was determined by comparing the concentration of nonradioactive T8 and T4 at the point at which binding of TH-'I was reduced by 50% from that found when no unlabeled T8 was added. Cross-reaction was less than 1: 5000 or less than a 1: 4185 molar ratio. There was significant cross-reaction of the T8 antibody to triiodothyroacetic acid (closed triangles) but none with tetrachlorothyronine (solid circles) or a variety of other related compounds (see text).
active iodine determinations. Patients with primary hypothyroidism had an elevated immunoassayable thyroid-stimulating hormone (TSH) level (31), defined as greater than 10 /AU/ml, and had no increase in the thyroidal uptake of radioiodine in response to five doses of 10 U of TSH every 12 hr. Those with hypopituitarism had definite clinical and laboratory evidence of failure of at least one other target organ, no immunoassayable TSH, and doubling of the thyroidal uptake of radioiodine in response to administration of exogenous TSH.
RESULTS

Methodological results
Cross-reaction with T4 and other compounds. The extent of cross-reaction between a T4 preparation, which had been purified chromatographically as described above, and the Ts antibody was determined by preparing standard curves for each hormone in a barbital diluent and comparing the concentration of nonradioactive Ts and To at the point at which binding of Ts-'I was reduced by 50% from that found when no unlabeled Ta was added. Cross-reaction was less than 1: 5000, or less than 1.4185 molar ratio (Fig. 1) . There was significant cross-reaction of the Ta antibody to triiodothyroacetic acid, a substance not normally present in the serum but none was found with tetrachlorothyronine (Fig. 1) tually identical (Fig. 2) . A curve constructed with dilutions of a hyperthyroid serum in place of exogenous T3 yielded a parallel curve (Fig. 2) In the absence of tetrachlorothyronine, almost no change was noted in the B/F ratio as the concentration of T3 increased in the serum assay mixture (Fig. 2) . Pilot experiments showed that the addition of tetrachlorothyronine caused a measurable change in the B/F ratio with increments of Ta. A change in the B/F ratio was seen with T3 additions when these were performed in the presence of 0.05 gg of tetrachlorothyronine per tube, and became more marked at 0.1 ltg. No further changes were found in the B/F ratio with additions of tetrachlorothyronine above 0.1 ,tg/tube. Therefore, it was decided to routinely add ia of a ixg of tetrachlorothyronine per assay tube. This resulted in a change in the B/F ratio sufficient to permit quantitation of 12.5 pg of T3. This lower limit of detectability (see below) corresponds to a serum concentration of 50 ng/100 ml when the assay is performed with 0.1 ml of serum (0.025 ml of serum per assay tube). Since some hypothyroid sera contain as little as 40-50 ng of T3/100 ml of serum, samples were requantitated using four times the usual amount of serum (and 0.8 Ag of tetrachlorothyronine per tube). Because of the additional total protein and TBG present, a separate serum standard was run for these samples with 0.1 ml of Tafree serum and 0.8 Ag of tetrachlorothyronine per assay tube.
The most sensitive portion of the curve i.e., where the slope is greatest, fell between 12.5 and 100 pg of Ta per tube, which corresponds to a serum concentration of up to 400 ng/100 ml. The hyperthyroid samples which contain concentrations of Ts greater than 400 ng/ 100 ml were remeasured after they had been diluted with 1: 4 in Ta-free serum, so that they also fell on this most sensitive portion. In rare samples with concentrations of T. above 1600 ng/100 ml, further dilution in T.-free serum was employed before measurement.
Effect of added T4. In view of the very minor crossreaction between the T3-antibody and T4, no significant effect on immunoassayable Ta would be anticipated from clinically observed variations in the T4 concentration. This was verified by remeasuring the Ts concentrations of a hypothyroid serum, which initially contained 60 ng/100 ml of Ta and less than 0.2 jtg/100 ml of T4 after adding 0.4, 2, 10, 20, and 40 Ag/100 ml of T4 in vitro. A similar series of determinations was performed on a T3-free serum sample, devoid of measurable T4 (i.e., less than 0.2 g/1lO0 ml of T4) to which 200 ng/100 ml of T3 had been added. In 
±3.0% (SD).
Comparison with measurements by gas chromatography. A gas-liquid chromatographic method (GLC) for the measurement of Ts in serum has been developed by our group and has been previously described in detail (10) . This technique consists of five fundamental steps: (a) extraction of Ts from serum by passage through a cation exchange resin column; (b) preparation of a stable, volatile derivative of T3; (c) purification of the derivative with an anion-exchange resin column; (d) gas chromatographic separation and quantitation utilizing a nickel-63 electron capture detector, and (e) correction for methodological conversion of T4 and T3. 28 sera were measured by radioimmunoassay and GLC and the results compared in Fig. 3 . The coefficient of the correlation for these measurements equaled 0.99. 
Serum Triiodothyronine by Radioimmunoassay and Gas Chromatography
The majority of measurements agreed within 10% and in no instance did the two determinations differ by more than 25%.
Clinical results. In 82 normal subjects, ranging in age from 20 to 60 yr, Ta ranged from 96 to 172 ng/100 ml with a mean of 138 ng/100 ml and a standard deviation of 23 ng/100 ml. Normal male and female subjects had comparable levels of circulating Ts and for this reason measurements in both sexes have been combined into a single range (Table I) . We have previously obtained a similar normal value, 137 ±23 ng/100 ml by gas-liquid chromatography (10) ( Table I) .
45 patients with primary hypothyroidism had a mean (±SD) serum Ts value of 62 ±9 ng/100 ml. This compares with the value of 68 ±12 ng/100 ml found with GLC (10) ( Table I) . Ta values in the hypothyroid group were about one-half that found in the normal subjects with no overlap between the two groups. In four cases of hypothyroidism secondary to hypopituitarism, the mean serum Ta was 57 ng/100 ml, slightly, but not statistically lower than in the primary group.
The mean Ta value in toxic diffuse goiter was 494 ng/100 ml and again there was no overlap with the normal group. The values had a somewhat wider range varying from 248 to 1700 ng/100 ml with a distribution skewed toward the lower numbers. This compares with a value of 510 ±131 ng/100 ml by GLC. One of a small group of four patients with toxic nodular goiter had a serum Ts of 1225 ng/100 ml but the other three had only modestly elevated values (232, 296, and 280 ng/100 ml).
The mean serum Ta was normal in patients with treated toxic diffuse goiter after they became euthyroid. It was 131 ng/100 ml in 60 patients who had been treated with radioiodine, 112 ng/100 ml in 11 patients after surgery, and 132 ng/100 ml in 21 patients after euthyroidism had been achieved during the course of antithyroid drug administration.
Of particular interest were the Ta values in a third group of 40 patients with a syndrome which we have called Ts toxicosis (7, 8) . These patients, the subjects of a detailed clinical report now in preparation, all had definite clinical evidence of hyperthyroidism but repeatedly normal measurements of total T4 (PBI and T4 by column or T4 by competitive binding analysis) and normal thyroxine-binding globulin capacities. The mean serum T3 in this group of patients was somewhat higher than that in the conventional form of hyperthyroidism, 712 ng/100 ml vs. 494 ng/100 ml, with a very wide range from 228 to greater than 2000 ng/100 ml ( Table  I) . Six of the patients with this variant of hyperthyroidism had localized accumulation of radioiodine in their glands in addition to a clinically palpable nodule; 34 had diffuse enlargement of their thyroid gland; 6 of 12 tested had measurable long-acting thyroid stimulator (LATS) and all 21 of those tested failed to show a decrease in thyroidal uptake of radioiodine after exogenous Ts.
DISCUSSION
Methodological variables. In order to validly apply the radioimmunoassay method to measurements of small amounts of Ts present in unextracted serum samples, four potential sources of error were considered: (a) Ts antibody may cross-react with T4 present in the sample and, therefore, yield a spuriously elevated value for T8. This was shown to be unimportant in this system since the T3 antibody-T4 interaction was less than 1: 5000th that of the antibody's reaction with Ts. (b) Competition for Ta by serum proteins which have a strong affinity for Ts, especially TBG, would interfere with the binding of T8 to antibody and lead to variations in the B/F ratio depending on their relative binding affinities. Binding of Ts to TBG was inhibited using 3,5,3',5'-D,L-tetrachlorothyronine, the chlorinated analogue of T4, which had been shown by Wolff, Standaert, and Rall to competitively inhibit T4 binding to TBG (23) . (c) Serum proteins are known to interfere with antigen-antibody reactions (32) so that even if serum binding of Ts is inhibited, a standard curve constructed in serum might differ from that obtained in the buffer and such a difference was actually observed in this study (Fig. 2 ).
This problem was solved by using, as a diluent, serum to which increasing amounts of Ts were added to construct the standard curves. (d) Serum from even the most hypothyroid subject contains some endogenous Ta. Measurements by the immunoassay method using a hypothyroid serum to construct a standard curve would be limited to those samples containing more Ts than in the serum diluent and even in these instances the estimated value would be diminished by the Ts content of the diluent. Therefore, a serum preparation, which contained less than 4 ng of Ta/100 ml, was prepared with triosorb sponges and used as the serum diluent. By using a T3-free serum as diluent, it was possible to develop an assay sufficiently sensitive to permit T3 quantitation and differentiation of normal, hypothyroid, and hyperthyroid subjects. When performed in this fashion, the radioimmunoassay procedure is an accurate measure of the concentration of Ts in the serum. This was documented in detail. Published determinations of the level of T3 in normal human serum have varied widely (7, 8, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) and the actual level has not been agreed upon. Our earlier estimates by gas-liquid chromatography (7) gave a falsely high value, because we failed to correct for methodological conversion of T4 to T3, i.e., deiodination of approximately 1.7% of endogenous T4 that occurs during the GLC procedure. With correction we now obtain values with gas-liquid chromatography which agree well with those reported here with radioimmunoassay (10) .
Two groups (17, 18) have published measurements of serum Ts in which they employed a competitive binding protein analysis method as the final quantitative step in their procedure. The values are significantly higher than those we have obtained. However, we have analyzed the extraction procedures and chromatography system used in these methods by gas chromatography and radioimmunoassay and have demonstrated that there is contamination of the Ts area on the paper chromatogram with 0.25 and 0.50% of the endogenous Ts in serum, as well as conversion (deiodination) of 0.20 and 0.25%, of the endogenous To to T3 during the extraction and separation procedures. These in vitro artifacts constitute a negligible proportion of the endogenous T4 but can cause an error of 50-100% or more in the measured T3 levels. We find that with one-dimensional paper chromatography, utilizing the t-amyl: alcohol: ammonia, t-amyl alcohol: hexane: ammonia, and butanol-ethanol: ammonia systems, T4 contamination in the Ts area can be minimized only by placing the strips in the chromatographic tank after the paper has thoroughly dried, but in confirmation of Taurog, we also find that this results in increased conversion of To to Ts during the chromatography (33 (37a) . (c) Iodine deprivation in experimental animals is also known to be associated with high serum T3 levels (38, 39) . More recently, in association with Drs. P. Malvaux and C. Beckers, we have found that normal subjects placed on a diet of less than 50 Ag of iodide per day had a high serum Ts (239 ng/100 ml vs. a normal of 139 ng/100 ml) and a low serum T4 suggesting that relative hypersecretion of T3 may represent an important homeostatic mechanism in the face of inadequate iodide substrate in man (40) . (d) Radechevich and Werner (41) noted that T3 was elevated in many patients with "hot nodules," i.e., patients having a localized accumulation of radioiodine in one area of their thyroid glands. We have found elevated serum T3 levels in 40% of patients with toxic adenomata as defined by Ingbar and Woeber (42) . Most of our patients with toxic adenomata did not have overt disease but had signs and symptoms compatible with mild thyrotoxicosis. (e) The serum T3 values in toxic diffuse goiter vary over a very wide range and were markedly skewed toward the lower portion of that range. We have previously found using GLC for the measurement of serum T3 and T4 that abnormally high T3/T4 ratios appear to correlate with the presence of long-acting thyroid stimulator (LATS) in the serum of untreated patients with toxic diffuse goiter. More recently we have observed with the immunoassay technique that Ta levels in euthyroid patients with treated toxic diffuse goiter are higher in those who have measurable LATS in their blood (43) . (f) Sterling and coworkers have noted the maintenance of normal clinical status in patients (44) with normal or elevated Ta but low serum T4 concentration after 13JI therapy for thyrotoxicosis. (g) Bowers, Schally, Hawley, Gual, and Parlow (45), Fleischer, Burgus, Vale, Dunn, and Guillemin (46) and many workers have recently demonstrated that intravenous administration of thyrotropin-releasing hormone (TRH) in man is followed by a prompt rise in circulating TSH.
Studies in our laboratory with intravenous administration of TRH have revealed elevations not only of TSH, but of T3 as well (47) . This finding would suggest that measurements of T3 levels after TRH administration may allow for a simple assessment of pituitary and thyroidal reserve.
In normal man, the physiological role of Ta relative to that of T4 remains to be established. Woeber and colleagues (48) measured serum Ta level and the rate of T3 clearance and found that the absolute Ta disposal averaged 60 Ag/day, a figure comparable with the 80 lyg of T4 which is turned over daily in normal subjects (49) . According to preliminary results of tracer studies now underway, we find similar kinetic data, but with our lower values for the serum T3 concentration, we calculate the T3 disposal rate to be somewhat lower, averaging [35] [36] [37] [38] [39] [40] pg/day. It should not be inferred that these values represent an accurate estimate of the relative rates of secretion of T3 and T4 from the thyroid gland, because recent observations (4) (5) (6) 50) suggest that a considerable proportion of circulating Ts derives from T4. Clearly, as Woeber and colleagues have pointed out (48) , available observations do not permit us to draw inferences with regard to relative metabolic contributions of the T4 and T3 secreted by the thyroid gland.
Finally, evidence is accumulating that plasma and cellular binding and metabolism of Ta differ strikingly from that of T4 (51) (52) (53) (54) and that these differences may be of major import in determining the relative metabolic potencies of the two hormones.
